All In Biotech

Drug Trial Radar · NCT06565689

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

A Multi-center, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

May 9, 2023

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to provide a basis for further clinical development of YK012.

Conditions

  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

  • YK012Drug

    YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs)Time frame: From the first infusion of YK012 until 28 Days after end of treatment
  2. The incidence and profile of dose-limiting toxicity (DLT)Time frame: 28 days after the first dose
  3. The maximum tolerated dose and/or the recommended dose for further clinical trialTime frame: 28 days after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.